Suppliers / Maithri Drugs

Maithri Drugs

India 231 employees Updated 9 July 2026

Maithri Drugs is an API manufacturer based in India. It holds 72 active US drug master files and 17 valid CEPs. Its GMP standing is certified by US FDA and EMA. Its most recent recorded inspection, by US FDA, closed on 20 June 2025 as VAI. Customs aggregates show $7.3M of exports covering 228 molecules to 37 destinations in 2025.

72
active US DMFs
17
valid CEPs
3
registered plants 1 with an FDA FEI number
2
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 20 June 2025 VAI US FDA
  • 22 November 2019 VAI US FDA
  • 25 August 2017 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Bonthapally Village, India Not on file
Sangareddy District, India 3012234942
Bonthapally, India Not on file

What they file, and where

Molecule Regulators Docs
Nitrofurantoin EDQM, US FDA 5
Selexipag SFDA (Saudi Arabia), US FDA 5
Mirtazapine EDQM, US FDA 4
Adapalene EDQM, US FDA 2
Brimonidine EDQM, US FDA 2
Carbidopa EDQM, US FDA 2
Carbimazole EDQM, US FDA 2
Chlorthalidone EDQM, US FDA 2
Dapoxetine SFDA (Saudi Arabia), US FDA 2
Doxycycline US FDA 2
Show all 30 molecules on file
Esketamine EDQM, US FDA 2
Foscarnet EDQM, US FDA 2
Ketamine EDQM, US FDA 2
Lercanidipine US FDA 2
Lercanidipine Hydrochloride EDQM 2
Levodopa EDQM, US FDA 2
Lithium Cation US FDA 2
Mesalazine EDQM, US FDA 2
Methimazole EDQM, US FDA 2
Potassium US FDA 2
Voriconazole US FDA 2
Abrocitinib US FDA 1
Avacopan US FDA 1
Besifloxacin US FDA 1
Cenobamate US FDA 1
Daridorexant US FDA 1
Deutetrabenazine US FDA 1
Dexmedetomidine US FDA 1
Docosanol US FDA 1
Efinaconazole US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
CDSCO (India) 2 None
US FDA None 1
EMA None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $1.6M 18
2025 Not reported $7.3M 37
2024 Not reported $4.5M 41
2023 Not reported $5.7M 33

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Maithri Drugs comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 20 June 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts